Current Report Filing (8-k)
January 13 2020 - 8:13AM
Edgar (US Regulatory)
Horizon Therapeutics Public Ltd Co 00-0000000 false 0001492426 0001492426 2020-01-13 2020-01-13
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 13, 2020
Horizon Therapeutics Public Limited Company
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Ireland
|
|
001-35238
|
|
Not Applicable
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File No.)
|
|
(IRS Employer
Identification No.)
|
Connaught House, 1st Floor, 1 Burlington Road, Dublin 4, D04 C5Y6, Ireland
(Address of principal executive offices)
Registrant’s telephone number, including area code: 011-353-1-772-2100
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Ordinary shares, nominal value $0.0001 per share
|
|
HZNP
|
|
The Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02
|
Results of Operations and Financial Condition.
|
On January 13, 2020, in advance of meetings and its presentation at the J.P. Morgan Healthcare Conference in San Francisco, California, Horizon Therapeutics plc issued a press release and is making publicly available a corporate presentation which include estimates of certain operating and financial results as of and for the year ended December 31, 2019, as well as other updates regarding its business. Copies of the press release and presentation are attached as Exhibits 99.1 and 99.2, respectively.
The information in this Item 2.02 and the exhibits thereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by reference in such filing.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
Date: January 13, 2020
|
|
|
|
HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Paul W. Hoelscher
|
|
|
|
|
|
|
Paul W. Hoelscher
|
|
|
|
|
|
|
Executive Vice President, Chief Financial Officer
|
Horizon Therapeutics Pub... (NASDAQ:HZNP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Horizon Therapeutics Pub... (NASDAQ:HZNP)
Historical Stock Chart
From Sep 2023 to Sep 2024